S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
S&P 500   3,370.29 (-0.29%)
DOW   29,232.19 (-0.56%)
QQQ   234.73 (+0.04%)
AAPL   319.00 (-1.83%)
FB   217.80 (+1.69%)
MSFT   187.23 (+1.01%)
GOOGL   1,519.44 (+0.05%)
AMZN   2,155.67 (+0.97%)
CGC   21.94 (-0.86%)
NVDA   296.57 (+2.34%)
BABA   220.52 (+0.41%)
MU   57.75 (-1.28%)
GE   12.75 (-0.62%)
TSLA   858.40 (+7.30%)
AMD   56.89 (+2.86%)
T   38.26 (+0.03%)
ACB   1.64 (+3.80%)
F   8.06 (-0.49%)
NFLX   387.78 (+1.94%)
PRI   135.62 (-0.89%)
BAC   34.27 (-1.66%)
DIS   139.14 (-0.29%)
GILD   67.01 (-0.81%)
Log in

NASDAQ:SRPT - Sarepta Therapeutics Stock Price, Forecast & News

$122.78
-2.64 (-2.10 %)
(As of 02/18/2020 04:00 PM ET)
Today's Range
$122.22
Now: $122.78
$126.41
50-Day Range
$111.62
MA: $123.65
$131.64
52-Week Range
$72.05
Now: $122.78
$158.80
Volume548,017 shs
Average Volume843,567 shs
Market Capitalization$9.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.2
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRPT
Previous SymbolNASDAQ:AVII
CUSIPN/A
Phone617-274-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$301.03 million
Book Value$15.45 per share

Profitability

Net Income$-361,920,000.00
Net Margins-169.87%

Miscellaneous

Employees499
Market Cap$9.15 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive SRPT News and Ratings via Email

Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.


Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics Inc (NASDAQ:SRPT) issued its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($1.70) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.35) by $0.35. The biotechnology company earned $99.04 million during the quarter, compared to analysts' expectations of $98.49 million. Sarepta Therapeutics had a negative net margin of 169.87% and a negative return on equity of 55.44%. The business's quarterly revenue was up 26.2% on a year-over-year basis. During the same period in the prior year, the business earned ($1.15) EPS. View Sarepta Therapeutics' Earnings History.

When is Sarepta Therapeutics' next earnings date?

Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Sarepta Therapeutics.

What guidance has Sarepta Therapeutics issued on next quarter's earnings?

Sarepta Therapeutics updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$370-380 million, compared to the consensus revenue estimate of $$383.65 million.

What price target have analysts set for SRPT?

24 brokers have issued 12-month target prices for Sarepta Therapeutics' stock. Their forecasts range from $170.00 to $270.00. On average, they expect Sarepta Therapeutics' stock price to reach $201.20 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price. View Analyst Price Targets for Sarepta Therapeutics.

What is the consensus analysts' recommendation for Sarepta Therapeutics?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 23 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sarepta Therapeutics.

What are Wall Street analysts saying about Sarepta Therapeutics stock?

Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
  • 1. Evercore ISI analysts commented, "We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well." (8/8/2019)
  • 2. According to Zacks Investment Research, "Sarepta's Exondys 51 has witnessed impressive growth in 2018. Sarepta is also focused on reimbursement programs for better accessibility of the drug. Moreover, a potential approval to golodirsen will boost the company’s prospect as it will increase eligible patient population. Sarepta’s continues to progress with its DMD pipeline. The company is collaborating with companies and academic institutions to boost its DMD pipeline. However, dependence on a single product, Exondys 51, remains a concern. Meanwhile in December 2018, the company received a setback as it failed to gain approval for Exondys 51 in the EU. The DMD market is getting competitive as several other companies are developing therapies. The company’s shares have underperformed the industry so far this year. Loss estimates have narrowed ahead of the company’s Q1 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (5/8/2019)
  • 3. Cantor Fitzgerald analysts commented, ": Reiterate our Overweight rating and 12-mo. PT of $217. From our conversations with investors, we believe that awareness on limb girdle is increasing, but it remains low. We are publishing our 35-page prep pack discussing the disease, data expectations and potential stock moves. Sarepta will disclose 60- day biopsy data for MYO-101 in LGMD2E patients on Wed. morning (2/27). This is the first of five limb girdle readouts in the pipeline, which we think could drive significant upside to current valuation and diversify Sarepta beyond DMD. Sarepta remains a top pick." (2/22/2019)

Has Sarepta Therapeutics been receiving favorable news coverage?

Press coverage about SRPT stock has trended extremely negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sarepta Therapeutics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Sarepta Therapeutics.

Are investors shorting Sarepta Therapeutics?

Sarepta Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 12,660,000 shares, an increase of 6.3% from the January 15th total of 11,910,000 shares. Based on an average trading volume of 1,322,000 shares, the days-to-cover ratio is presently 9.6 days. Currently, 17.9% of the shares of the stock are sold short. View Sarepta Therapeutics' Current Options Chain.

Who are some of Sarepta Therapeutics' key competitors?

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Advanced Micro Devices (AMD), Tesla (TSLA), ACADIA Pharmaceuticals (ACAD) and Bausch Health Companies (BHC).

Who are Sarepta Therapeutics' key executives?

Sarepta Therapeutics' management team includes the folowing people:
  • Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)
  • Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)
  • Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)
  • Dr. Edward M. Kaye, Advisor (Age 70)

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sands Capital Management LLC (6.11%), Janus Henderson Group PLC (4.25%), Capital Research Global Investors (3.23%), Fred Alger Management LLC (1.16%), Jennison Associates LLC (1.03%) and Casdin Capital LLC (0.90%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme. View Institutional Ownership Trends for Sarepta Therapeutics.

Which major investors are selling Sarepta Therapeutics stock?

SRPT stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, FIL Ltd, Cadian Capital Management LP, Point72 Asset Management L.P., Jennison Associates LLC, Boxer Capital LLC, Casdin Capital LLC and Alyeska Investment Group L.P.. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell and Sandesh Mahatme. View Insider Buying and Selling for Sarepta Therapeutics.

Which major investors are buying Sarepta Therapeutics stock?

SRPT stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Sands Capital Management LLC, Bessemer Group Inc., Kam Lawrence, California Public Employees Retirement System, UBS Asset Management Americas Inc. and Marshall Wace North America L.P.. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney and Richard Barry. View Insider Buying and Selling for Sarepta Therapeutics.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $122.78.

How big of a company is Sarepta Therapeutics?

Sarepta Therapeutics has a market capitalization of $9.15 billion and generates $301.03 million in revenue each year. The biotechnology company earns $-361,920,000.00 in net income (profit) each year or ($5.46) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe.View Additional Information About Sarepta Therapeutics.

What is Sarepta Therapeutics' official website?

The official website for Sarepta Therapeutics is http://www.sareptatherapeutics.com/.

How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]


MarketBeat Community Rating for Sarepta Therapeutics (NASDAQ SRPT)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,288 (Vote Outperform)
Underperform Votes:  763 (Vote Underperform)
Total Votes:  2,051
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel